Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes
  • Published Date:
    Mar 23 2010
  • Source:
    Diabetes Care. 33(6):1193-1199.
Filetype[PDF-159.21 KB]


Details:
  • Alternative Title:
    Diabetes Care
  • Personal Author:
  • Description:
    OBJECTIVE

    To assess the long-term cost-effectiveness of aspirin use among adults aged ≥40 years with newly diagnosed type 2 diabetes.

    RESEARCH DESIGN AND METHODS

    We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of use or nonuse of aspirin. The model simulates the progression of diabetes and accompanying complications for a cohort of subjects with type 2 diabetes. The model predicts the outcomes of type 2 diabetes along five disease paths (nephropathy, neuropathy, retinopathy, coronary heart disease, and stroke) from the time of diagnosis until age 94 years or until death.

    RESULTS

    Over a lifetime, aspirin users gained 0.31 life-years (LY) or 0.19 quality-adjusted LYs (QALYs) over nonaspirin users, at an incremental cost of $1,700; the incremental cost-effectiveness ratio (ICER) of aspirin use was $5,428 per LY gained or $8,801 per QALY gained. In probabilistic sensitivity analyses, the ICER was <$30,000 per QALY in all of 2,000 realizations in two scenarios.

    CONCLUSIONS

    Regular use of aspirin among people with newly diagnosed diabetes is cost-effective.

  • Subject:
  • Document Type:
    Journal Article
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
No Related Documents.
You May Also Like:
  1. Use of selected clinical preventive services among adults--United States, 2007-2010
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    June 15, 2012
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 61, suppl. (June 15, 2012)
    Description:
    "CDC has a long history of monitoring the use of clinical preventive services to provide public health agencies, health care providers and their partners information needed to plan and implement programs that increase use of these services and improv...
    File Type:
    Filetype[PDF - 64.41 MB]
  2. When is Genomic Testing Cost-Effective? Testing for Lynch Syndrome in Patients with Newly-Diagnosed Colorectal Cancer and Their Relatives
    Personal Author:
    Grosse, Scott D.
    Published Date:
    2015
    Source:
    Healthcare (Basel). 3(4):860-878.
    Description:
    Varying estimates of the cost-effectiveness of genomic testing applications can reflect differences in study questions, settings, methods and assumptions. This review compares recently published cost-effectiveness analyses of testing strategies for L...
    File Type:
    Filetype[PDF - 231.06 KB]
  3. Enhancing use of clinical preventive services among older adults; closing the gap
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). AARP (Organization). Centers for Medicare & Medicaid Services (U.S.). United States, Administration on Aging.. United States, Agency for Health Care Policy and Research..
    Published Date:
    2011
    Description:
    This new report, Enhancing Use of Clinical Preventive Services Among Older Adults -- Closing the Gap, calls attention to the use of potentially lifesaving preventive services by our nation's growing population of adults aged 65 years and older. By pr...
    File Type:
    Filetype[PDF - 10.11 MB]
  4. MMWR. Morbidity and mortality weekly report, Vol. 64, no. 27, July 17, 2015
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    July 17, 2015
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 64, no. 27
    File Type:
    Filetype[PDF - 754.84 KB]
  5. A Purchaser's guide to clinical preventive services; moving science into coverage
    Personal Author:
    Campbell, Kathryn Phillips; Lanza, Andrew;
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.). U.S. Preventive Services Task Force. United States, Agency for Healthcare Research and Quality.. Washington Business Group on Health.
    Published Date:
    2006
    Description:
    "A Purchaser's Guide to Clinical Preventive Services: Moving Science into Coverage (Purchaser's Guide) is an information source for employers on clinical preventive service benefit design. This document provides guidance for the selection of clinical...
    File Type:
    Filetype[PDF - 2.08 MB]